Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer

Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer

Androgen receptor (AR)-castrate-resistant prostate cancer (CRPC) is an aggressive form of prostate cancer that does not have clinically approved targeted treatment options. To this end, the cytotoxic potential of raloxifene and the synthetic curcumin derivative 2,6-bis (pyridin-4-ylmethylene)-cycloh...

Full description

Bibliographic Details
Main Authors: Hannah Palmer, Mhairi Nimick, Aloran Mazumder, Sebastien Taurin, Zohaib Rana, Rhonda J. Rosengren
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
CRPC
AR-prostate cancer
raloxifene
curcumin derivative
combination therapy
anti-cancer agent
Online Access:https://www.mdpi.com/2227-9059/10/4/853

Similar Items

Similar Items